Concepedia

Yuhei Harutani

YH

Statistics

Publications

5

Citations

165

H-Index

5

Active since

2019

Affiliations

Wakayama Medical University(Current)

Nagasaki University

Japanese Foundation For Cancer Research

National Hospital Organization

Tohoku University

Yuhei Harutani is an author at Wakayama Medical University specializing in oncology, immune checkpoint inhibitors, and immunotherapy.

Publications per year

2019–2023

5

Publications

5

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer

Hiroaki Akamatsu, Eriko Murakami, Jun Oyanagi et al. · The Oncologist · 2019 · 79 citations · Full text

, , +17

Histologic transformation of epidermal growth factor receptor–mutated lung cancer

Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto et al. · European Journal of Cancer · 2022 · 28 citations

, , +16

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer

Siew‐Kee Low, Ryo Ariyasu, Ken Uchibori et al. · Translational Lung Cancer Research · 2022 · 28 citations · Full text

, , +17

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi et al. · Cancer Science · 2020 · 16 citations · Full text

, , +17

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer

Shinsuke Ogusu, Yuhei Harutani, Takehiro Tozuka et al. · Cancer Immunology Immunotherapy · 2023 · 14 citations · Full text

, , +17

1–5 of 5